Durvalumab

Sarah Cannon Research Institute to Present Latest Cancer Research Insights at 2024 ASCO® Annual Meeting

Retrieved on: 
星期四, 五月 30, 2024
Research, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Relapse, Follicular lymphoma, Paclitaxel, Finish line, Drug development, Metastatic breast cancer, Breast cancer, Tumor microenvironment, Sarah Cannon Research Institute, Breast, Lead, Master, Consolidation, HealthOne, Durvalumab, Meta-analysis, CDT, OU Health, Total cost, PD-L1, Survival, Clinical trial, Quality, MPH, Endometrial cancer, NSCLC, SCRI, ASCO, Safety, BCMA, Society, Cetuximab, Doctor of Philosophy, Efficacy, Spacecraft, Metastasis, Monoclonal antibody, Acute myeloid leukemia, Abstract, HCA Healthcare, Role, Annual general meeting, Birth control

“We look forward to connecting with colleagues from around the world at ASCO’s Annual Meeting to discuss the latest developments in advancing therapies for cancer patients,” says Howard A.

Key Points: 
  • “We look forward to connecting with colleagues from around the world at ASCO’s Annual Meeting to discuss the latest developments in advancing therapies for cancer patients,” says Howard A.
  • To learn more about our research experts, visit our Leadership Page .
  • “Clinical Trial Participation and End-of-Life Care Among Older Adults: A Multi-Center Longitudinal Observational Cohort Analysis of 121,717 Patients with Cancer,” Dr.
  • “Performance of Comprehensive Genomic Profiling versus Single Gene Testing in Guideline-Recommended Biomarker Selection in Non-Small Cell Lung Cancer,” Dr. V. Subbiah, 1:30 p.m. - 4:30 p.m. CDT, Hall A.

Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients

Retrieved on: 
星期二, 三月 26, 2024
Research, Head, Clinical Cancer Research, Immunotherapy, Patient, Tumor microenvironment, Durvalumab, Cancer, AI, CCR, AACR, Phenotype, Yonsei University, Immune system, Therapy

SEOUL, South Korea, March 26, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the publication of a new study featuring Lunit SCOPE IO, Lunit's AI-powered analyzer for quantitative immune phenotyping from H&E. The study was recently published in Clinical Cancer Research (CCR), an international journal by the American Association for Cancer Research (AACR).

Key Points: 
  • The study was recently published in Clinical Cancer Research (CCR), an international journal by the American Association for Cancer Research (AACR).
  • This investigation addresses the current lack of exploration into the clinical implications of neoadjuvant immunotherapy in HNSCC patients with resectable tumors, utilizing Lunit SCOPE IO to examine the changes in tumor microenvironment when treated with durvalumab and tremelimumab.
  • "Through this prospective clinical study, we have confirmed the clinical utility of preoperative immunotherapy for treating locally advanced head and neck cancer," said Professor Kim Hye Ryun, head of the research.
  • "In this study, Lunit SCOPE IO provides deeper insights into the tumor microenvironment and immune response, empowering healthcare professionals with invaluable information to make more informed treatment decisions.

RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer

Retrieved on: 
星期四, 十二月 21, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Associate, Cougar, Wilfrid Sellars, Cholangiocarcinoma, Blood, Hematology, NDA, MD, Radiology, Clinical trial, Glomus tumor, University, Pancreatic cancer, University of Oklahoma, Durvalumab, Interventional radiology, Patient, Safety, Senior, Medical imaging

The CouGar Trial will evaluate RenovoGem in bile duct cancer, specifically unresectable locally advanced extrahepatic cholangiocarcinoma (eCCA).

Key Points: 
  • The CouGar Trial will evaluate RenovoGem in bile duct cancer, specifically unresectable locally advanced extrahepatic cholangiocarcinoma (eCCA).
  • “We are pleased to engage our first clinical site for our second pivotal clinical trial.
  • The CouGar Trial marks an important milestone for RenovoRx as we expand our clinical pipeline for RenovoGem into bile duct cancer, a difficult-to-treat solid tumor cancer,” said Leesa Gentry, Senior Vice President of Clinical Operations at RenovoRx.
  • Oklahoma University (OU) Health is the first clinical site for the CouGar study.

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

Retrieved on: 
星期一, 十一月 13, 2023
Durvalumab, Neck, Research, NYSE, Shield, GMP, Safety, Telephone, Head, Conference call, Clinical trial, ESMO, HCT, Patient, FDA, Cancer, VCN, Therapy, Conference, University, SITC, Survival, Congress, CPS, KOL, ICO, Travel, University of Pennsylvania, Pharmaceutical industry, Cryptocurrency, PDAC

ET -

Key Points: 
  • ET -
    ROCKVILLE, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
  • Third Quarter Ended September 30, 2023 Financial Results
    General and administrative expenses decreased to $212,000 for the three months ended September 30, 2023, from $2.4 million for the three months ended September 30, 2022.
  • Theriva Biologics will host a conference call on Monday, November 13, 2023, at 8:30 a.m.
  • ET to discuss its financial results for the quarter ended September 30, 2023 and provide a corporate update.

Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes

Retrieved on: 
星期一, 十二月 18, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Durvalumab, PD-L1, Breast, Safety, Research, AstraZeneca, Neoadjuvant therapy, ADC, Breast cancer, Patient, Neoplasm, TSE, DXD, Prognosis, HER2, MD, Survival, HR, Recurrence, Immunotherapy, CPS, TNBC, Pharmaceutical industry, Medical imaging, Daiichi Sankyo

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo and AstraZeneca.

Key Points: 
  • Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo and AstraZeneca.
  • TROPION-Breast04 is evaluating neoadjuvant datopotamab deruxtecan plus durvalumab followed by adjuvant durvalumab with or without chemotherapy in patients with stage II-III triple negative breast cancer (TNBC) or hormone receptor (HR) low, HER2 low or negative breast cancer.
  • TROPION-Breast05 is evaluating datopotamab deruxtecan alone and in combination with durvalumab in patients with locally recurrent inoperable or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10).
  • TROPION-Breast03 is evaluating datopotamab deruxtecan with and without durvalumab versus investigator’s choice of therapy in patients with stage I to III TNBC with residual disease after neoadjuvant therapy.

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023

Retrieved on: 
星期一, 十月 23, 2023
Neoplasm, Survival, PD-L1, Q&A, NYSE, ESMO, Therapy, SS, Congress, Head, European Society for Medical Oncology, PFS, Vice, CS, The Catalan Institute for Water Research, Poster, L'Hospitalet, CD8, CPS, Immunotherapy, KOL, Oncology, L'Hospitalet de Llobregat, ICO, Cancer, Opinion, Patient, OS, Neck, Pharmaceutical industry, Palladium, Vaccine, Medical imaging, Durvalumab

ROCKVILLE, Md., Oct. 23, 2023 (GLOBE NEWSWIRE) --  Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced new clinical data from the Phase 1 investigator-sponsored study with the Institut Catala d’Oncologia (ICO) evaluating VCN-01 in combination with durvalumab for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). These data were presented at the European Society for Medical Oncology (ESMO) Congress, held both virtually and in Madrid, Spain from October 20-24, 2023.

Key Points: 
  • These data were presented at the European Society for Medical Oncology (ESMO) Congress, held both virtually and in Madrid, Spain from October 20-24, 2023.
  • These results build on the previously reported acceptable safety profile seen with sequential dosing of VCN-01 and durvalumab.
  • Key Takeaway: VCN-01 combined with durvalumab showed encouraging overall survival (OS) in patients who previously progressed on anti-PD(L)-1 therapy.
  • VCN-01 combined with durvalumab increased CD8 T cells, a marker of tumor inflammation and the expression of PD(L)-1 in tumors.

Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial

Retrieved on: 
星期日, 十月 22, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Neoplasm, Appetite, DXD, PRS, PD-L1, Constipation, AstraZeneca, PD, Vomiting, Stomatitis, Congress, European Society for Medical Oncology, PFS, MD, CRS, HIV disease progression rates, TNBC, ADC, Dor, TSE, Breast cancer, ORR, ILD, Arm, Patient, Breast, Barts and The London School of Medicine and Dentistry, Fatigue, Medical imaging, Pharmaceutical industry, Daiichi Sankyo, Durvalumab

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).

Key Points: 
  • Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).
  • “These results for datopotamab deruxtecan plus durvalumab in the first-line triple negative breast cancer setting are highly encouraging, particularly the 79% objective response rate,” said Peter Schmid, MD, Barts Cancer Institute, London, United Kingdom, and investigator in the trial.
  • “Disease progression after initial treatment is a reality for patients with triple negative breast cancer, underscoring the need for more durable treatment options,” said Mark Rutstein, MD, Global Head, Oncology Clinical Development, Daiichi Sankyo.
  • As of the February 2, 2023 data cut-off, 29 patients (47%) remained on study treatment.

Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Retrieved on: 
星期一, 十月 16, 2023
Congress, Cancer, NYSE, OS, PD-L1, Therapy, KOL, Survival, Disease, CEST, Oncology, ESMO, CD8, SS, Neck, Vice, Opinion, The Catalan Institute for Water Research, Patient, Head, Durvalumab, Q&A, European Society for Medical Oncology, ICO, CPS, Neoplasm, L'Hospitalet, Poster, Pharmaceutical industry, Vaccine, Medical imaging, CS

ROCKVILLE, Md., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced a presentation of Phase 1 data from the investigator-sponsored study evaluating VCN-01 in combination with durvalumab for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). Encouraging survival was observed in patients progressing to anti-PD(L)-1 agents after systemic VCN-01 in combination with durvalumab. Data will be featured in a poster presentation at the European Society for Medical Oncology (ESMO) Congress, being held both virtually and in Madrid, Spain from October 20-24, 2023.

Key Points: 
  • Encouraging survival was observed in patients progressing to anti-PD(L)-1 agents after systemic VCN-01 in combination with durvalumab.
  • Data will be featured in a poster presentation at the European Society for Medical Oncology (ESMO) Congress, being held both virtually and in Madrid, Spain from October 20-24, 2023.
  • In the CS cohort at the 3.3×1012 viral particles (vp) dose, overall survival (OS) was 10.4 months.
  • 11 patients (61.1%) were alive >12 months (2 in CS; 5 in SS at 3.3×1012vp, 4 in SS at 1×1013 vp).

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

Retrieved on: 
星期五, 十月 13, 2023
MBA, NYSE, Colorectal cancer, RET, Safety, US Foods, Therapy, Oncolytics Biotech, Breakthrough therapy, Transfection, News, NRG1, Research, Eli Lilly and Company, Cancer, HIV disease progression rates, Gastrointestinal cancer, JD, MD Anderson Cancer Center, AstraZeneca, LLY, EDB, Spacecraft, TSX, Eye, Pyxis, Liver, Disease, System, FDA, RECIST, University, Pancreatic Cancer Action Network, Thorax, Immunotherapy, FTD, Extracellular matrix, Fusion, Neoplasm, Congress, GI, Incidence, ORR, MD, ONC, Meru Networks, Colon, AZN, Pancreatic cancer, Patient, BTC, Johns Hopkins University, Pharmaceutical industry, Durvalumab, Lancet

VANCOUVER, BC, Oct. 13, 2023 /PRNewswire/ -- USA News Group  -  Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the deadliest cancers on earth, analysis published in The Lancet in April 2023 showed a rising incidence of pancreatic cancer among individuals younger than 55 years, further demonstrating a need for more treatments. Among the treatments in development that caught the eye of the FDA over the past year are those that have come from  Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Pyxis Oncology, Inc. (NASDAQ: PYXS), AstraZeneca PLC (NASDAQ: AZN), Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS).

Key Points: 
  • A lot of the main efforts in fighting this particular cancer are in line with the work of the Pancreatic Cancer Action Network (PanCAN).
  • They've been asking supporters from every state in the US to get in touch with Congress to boost federal funds for pancreatic cancer research.
  • Near the end of 2022, the FDA rewarded pelareorep with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • Out of the 13 patients checked, one had a complete response - something that doesn't happen often when treating pancreatic cancer.

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

Retrieved on: 
星期五, 十月 13, 2023
MBA, NYSE, Colorectal cancer, RET, Safety, US Foods, Therapy, Oncolytics Biotech, Breakthrough therapy, Transfection, News, NRG1, Research, Eli Lilly and Company, Cancer, HIV disease progression rates, Gastrointestinal cancer, JD, MD Anderson Cancer Center, AstraZeneca, LLY, EDB, Spacecraft, TSX, Eye, Pyxis, Liver, Disease, System, FDA, RECIST, University, Pancreatic Cancer Action Network, Thorax, Immunotherapy, FTD, Extracellular matrix, Fusion, Neoplasm, Congress, GI, Incidence, ORR, MD, ONC, Meru Networks, Colon, AZN, Pancreatic cancer, Patient, BTC, Johns Hopkins University, Pharmaceutical industry, Durvalumab, Lancet

VANCOUVER, BC, Oct. 13, 2023 /PRNewswire/ -- USA News Group  -  Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the deadliest cancers on earth, analysis published in The Lancet in April 2023 showed a rising incidence of pancreatic cancer among individuals younger than 55 years, further demonstrating a need for more treatments. Among the treatments in development that caught the eye of the FDA over the past year are those that have come from  Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Pyxis Oncology, Inc. (NASDAQ: PYXS), AstraZeneca PLC (NASDAQ: AZN), Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS).

Key Points: 
  • A lot of the main efforts in fighting this particular cancer are in line with the work of the Pancreatic Cancer Action Network (PanCAN).
  • They've been asking supporters from every state in the US to get in touch with Congress to boost federal funds for pancreatic cancer research.
  • Near the end of 2022, the FDA rewarded pelareorep with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • Out of the 13 patients checked, one had a complete response - something that doesn't happen often when treating pancreatic cancer.